Filtered By:
Condition: Thrombosis
Drug: Pradaxa
This page shows you your search results in order of relevance. This is page number 14.
Order by Relevance | Date
Total 508 results found since Jan 2013.
Impact of the COVID-19 pandemic on England's national prescriptions of oral vitamin K antagonist (VKA) and direct-acting oral anticoagulants (DOACs): An interrupted time series analysis (January 2019 - February 2021)
Conclusion: The overall oral anticoagulants use in this period was lower than expected, indicating a medical needs gap, possibly due to adherence issues. The potential clinical and logistical consequences warrant further study to identify contributing factors and mitigate avoidable risks.PMID:35582854 | DOI:10.1080/03007995.2022.2078100
Source: Current Medical Research and Opinion - May 18, 2022 Category: Research Authors: Sajidah Alkhameys Ravina Barrett Source Type: research
Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review
CONCLUSIONS AND RELEVANCE: Dose adjustment and low-intensity treatment are 2 different forms of dose-reduced DOACs. Dose adjustment is mostly relevant for AF and should be done based on the approved criteria. Dose adjustment of DOACs should not be used for acute VTE treatment in most cases. In contrast, low-intensity DOACs may be used for primary or secondary VTE prevention for studied and approved indications. Attention should be given to routine practice patterns to align the daily clinical practice with existing evidence of safety and efficacy.PMID:35648414 | DOI:10.1001/jamacardio.2022.1292
Source: Atherosclerosis - June 1, 2022 Category: Cardiology Authors: Behnood Bikdeli Farbod Zahedi Tajrishi Parham Sadeghipour Azita H Talasaz John Fanikos Giuseppe Lippi Deborah M Siegal John W Eikelboom Manuel Monreal David Jimenez Jean M Connors Walter Ageno Geoffrey D Barnes Gregory Piazza Dominick J Angiolillo Sahil A Source Type: research
Efficacy and safety of direct oral anticoagulants in the treatment of left ventricular thrombus after acute anterior myocardial infarction in patients who underwent percutaneous coronary intervention
CONCLUSIONS: DOACs appears to be a suitable alternative to warfarin for the management of LVT post STEMI, especially in patients who are intolerant to warfarin.PMID:36200193 | DOI:10.2174/1570161120666221003104821
Source: Current Vascular Pharmacology - October 6, 2022 Category: Drugs & Pharmacology Authors: Jing Liang Zhijian Wang Yujie Zhou Hua Shen Meng Chai Xiaoteng Ma Hongya Han Qiaoyu Shao Qiuxuan Li Source Type: research
